A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD)
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Rocatinlimab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ROCKET-VOYAGER
- Sponsors Amgen
Most Recent Events
- 08 Mar 2025 According to an Amgen media release, results from this trial will be presented at upcoming congresses or published in peer-reviewed journals.
- 17 Dec 2024 Status changed from active, no longer recruiting to completed.
- 06 Mar 2024 Planned End Date changed from 7 Nov 2024 to 6 Nov 2024.